EGFR and non-small cell lung carcinoma: To the best of our knowledge, this study represents the first cost-effectiveness analysis comparing rilertinib versus osimertinib, both the first-in-class and third-generation EGFR-TKI, for treating locally advanced or metastatic NSCLC in adult patients with confirmed EGFR T790M mutation after progression on prior EGFR TKIs therapy.